#United States #Boston #Outcomes4Me #Labcorp #HER2-low

Outcomes4Me and Labcorp Study Unveils Importance of Digital Education for Breast Cancer Patients

In a groundbreaking study set to be showcased at the 2024 San Antonio Breast Cancer Symposium on December 13, Outcomes4Me Inc. and Labcorp have revealed significant findings regarding the importance of digital education in increasing awareness of HER2-low status among metastatic breast cancer patients. This initiative sheds light on how effective communication and information dissemination can lead patients to better advocate for their health.

Outcomes4Me, known for its innovative AI-driven cancer platform, collaborated with Labcorp, a leader in laboratory services, focusing on enhancing biomarker awareness. The research arose following the revelatory results from the DESTINY-BREAST04 trial, which identified HER2-low as a crucial biomarker for understanding metastatic breast cancer (mBC).

Maya R. Said, CEO of Outcomes4Me, states that many patients suffering from mBC could substantially benefit from a thorough understanding of their HER2-low status. She emphasized the pressing need for timely transmission of clinical research into practical applications for patients. With this understanding, Outcomes4Me aimed to accelerate patient awareness through direct interaction.

The educational campaign designed by Outcomes4Me and Labcorp comprised several components tailored for patient engagement. This included a doctor-patient discussion guide, a webinar, and user-friendly content focused on HER2-testing and the implications of HER2-low breast cancer. Through these initiatives, patients were empowered to have meaningful discussions with their healthcare providers.

Dr. Rebecca Previs, Director of Medical Affairs at Labcorp, expressed her enthusiasm about the collaboration. She remarked that empowering patients with relevant information is paramount in guiding them towards making knowledgeable decisions about their treatment and discussions with healthcare professionals.

Initial surveys conducted before the campaign revealed startling gaps in awareness. Approximately 41.9% of patients were not significantly aware of their HER2 status. Additionally, over 51.3% reported that their oncologists did not mention HER2-low as a potential classification during previous consultations. These findings underscore the necessity of enhancing communication regarding HER2 status, as advancements in testing methodologies continue to evolve.

After engaging with the educational materials offered through the Outcomes4Me app, findings showed a remarkable change: 60.9% of patients previously unaware of their HER2 status indicated they would be likely to discuss HER2 testing with their oncologist. This campaign ultimately highlights the effectiveness of targeted educational interventions in fostering discussions about crucial health discussions among patients and healthcare providers.

The study exemplifies the vital role of collaboration between diagnostic firms and digital health platforms. By engaging patients directly and providing them with valuable knowledge, both organizations aim to improve biomarker testing rates, thus enhancing patient outcomes across the board.

On December 13, from 12:00 PM to 2:00 PM, the complete findings will be available for viewing at the San Antonio Breast Cancer Symposium, where Outcomes4Me will also be displaying their innovative services at Booth #1250.

In conclusion, as healthcare becomes more patient-centered, initiatives like those undertaken by Outcomes4Me and Labcorp symbolize a step towards empowering patients with knowledge and resources to navigate their cancer journey effectively. Moving forward, these educational efforts can pave the way for enhanced treatment accessibility, ensuring every patient can advocate for their health.